Mumbai, June 13 -- The pharmaceutical major has collaborated with MSN Laboratories (MSN), a leading pharmaceutical company in India, on this product.

Dr. Reddy's holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.

Bosutinib Tablets was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S.

The Bosulif brand had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.

Milan Kalawadia, CEO- North America, Dr. Reddy's Laboratories, Inc. said: "This launch highlights our commitment to leading with time...